Antonio Salerno
Research Subjects
Antonio Salerno has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Elizabeth Wenzel
Department of Psychiatry and Neurobehavioral Sciences,University of Virginia,Charlottesville,United States, USA
1 shared publication - Graziano Pinna
The Psychiatric Institute, Department of Psychiatry, College of Medicine, University of Illinois Chicago, Chicago, IL, USA; UI Center on Depression and Resilience (UICDR), Department of Psychiatry, College of Medicine, University of Illinois Chicago, Chicago, IL, USA; Center for Alcohol Research in Epigenetics (CARE), Department of Psychiatry, College of Medicine, University of Illinois Chicago, Chicago, IL, USA
1 shared publication - Jennifer L. Payne
University of Virginia, Charlottesville, USA
1 shared publication - John M. Davis
Psychiatric Institute, University of Illinois at Chicago, Chicago, IL, USA; Maryland Psychiatric Research Center, Baltimore, MD, USA
1 shared publication - Jordan C. Barone
University of Illinois at Chicago Chicago Illinois USA
1 shared publication - Liisa Hantsoo
Department of Psychiatry and Behavioral Sciences, Reproductive Mental Health Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
1 shared publication
Latest Publications
- Open Access
- 22 October 2026
- Published by MDPI AG in Preprints.org
A Blood-Based Platform for Integrated GABAergic, Neurosteroidogenic, and Epigenetic Profiling in Women’s Mental Health and Beyond
Women’s mental health remains underrepresented in biomedical research despite the substantial burden associated with postpartum depression, premenstrual dysphoric disorder, anxiety disorders, major depressive disorder, and related psychiatric conditions that are more common in women than men. Progress in biological characterization and biomarker development has been constrained by the limited availability of validated, standardized methods that account for reproductive stage, hormonal fluctuations, and sex-specific biology. Neuroactive steroids, including allopregnanolone, regulate neuronal excitability and stress responsivity through modulation of γ-aminobutyric acid type A (GABA-A) receptors. Alterations in neurosteroid biosynthesis, GABA-A receptor plasticity, and their coordinated regulation may therefore contribute to vulnerability across reproductive transitions and other periods of increased risk for mood disorders. Moreover, genes encoding neurosteroidogenic enzymes and GABA-A receptor subunits are susceptible to epigenetic regulation in response to hormonal, inflammatory, traumatic, and environmental exposures. This study aims to establish and validate a blood-based molecular platform for detecting and quantifying the expression of GABA-A receptor subunits; neurosteroidogenic enzymes, including 5α-reductase types 1 and 2, 5β-reductase, and 3α- and 3β-hydroxysteroid dehydrogenases; and epigenetic regulators from the ten-eleven translocation, histone deacetylase, and DNA methyltransferase. Whole blood provides a minimally invasive matrix suitable for repeated longitudinal assessment. Integrating these neurobiological signatures may provide a more comprehensive representation of the neurosteroid–GABAergic axis and its epigenetic regulation than examining individual markers alone. This methodological platform is intended to support future studies of biological vulnerability, disease progression, and treatment response, thereby facilitating the translation of experimental neurosteroid research into clinically relevant applications in women’s mental health and psychiatric populations more broadly.
- 22 October 2026
- Published by MDPI AG in Preprints.org
Open AccessA Blood-Based Platform for Integrated GABAergic, Neurosteroidogenic, and Epigenetic Profiling in Women’s Mental Health and Beyond
Women’s mental health remains underrepresented in biomedical research despite the substantial burden associated with postpartum depression, premenstrual dysphoric disorder, anxiety disorders, major depressive disorder, and related psychiatric conditions that are more common in women than men. Progress in biological characterization and biomarker development has been constrained by the limited availability of validated, standardized methods that account for reproductive stage, hormonal fluctuations, and sex-specific biology. Neuroactive steroids, including allopregnanolone, regulate neuronal excitability and stress responsivity through modulation of γ-aminobutyric acid type A (GABA-A) receptors. Alterations in neurosteroid biosynthesis, GABA-A receptor plasticity, and their coordinated regulation may therefore contribute to vulnerability across reproductive transitions and other periods of increased risk for mood disorders. Moreover, genes encoding neurosteroidogenic enzymes and GABA-A receptor subunits are susceptible to epigenetic regulation in response to hormonal, inflammatory, traumatic, and environmental exposures. This study aims to establish and validate a blood-based molecular platform for detecting and quantifying the expression of GABA-A receptor subunits; neurosteroidogenic enzymes, including 5α-reductase types 1 and 2, 5β-reductase, and 3α- and 3β-hydroxysteroid dehydrogenases; and epigenetic regulators from the ten-eleven translocation, histone deacetylase, and DNA methyltransferase. Whole blood provides a minimally invasive matrix suitable for repeated longitudinal assessment. Integrating these neurobiological signatures may provide a more comprehensive representation of the neurosteroid–GABAergic axis and its epigenetic regulation than examining individual markers alone. This methodological platform is intended to support future studies of biological vulnerability, disease progression, and treatment response, thereby facilitating the translation of experimental neurosteroid research into clinically relevant applications in women’s mental health and psychiatric populations more broadly.